openPR Logo
Press release

Profacgen Provides Protein Ubiquitination Services to Accelerate Drug Development Project

05-27-2022 10:54 AM CET | Health & Medicine

Press release from: Profacgen

Profacgen, an experienced provider in biological research and drug discovery, provides various ubiquitin services to help customers accelerate research progress and obtain better results.

Ubiquitination is one of the most prevalent post-translational modifications (PTMs) in cells. Ubiquitin modification induces protein degradation, which affects the function, localization, and activity of proteins. Therefore, the study of protein ubiquitination plays an important role in cell biology and drug discovery.

With the comprehensive advanced platform, Profacgen offers its customers the following services:

In Vitro ubiquitin conjugation reactions
Profacgen provides services to perform ubiquitin reactions in vitro and analyze the results.

Assay to measure protein ubiquitination in living cells
Profacgen provides ubiquitin assays that can measure all types of ubiquitination on a target protein in living cells. With the help of bioluminescence resonance energy transfer (BRET) methods, customers are able to study the dynamic ubiquitination of target protein and understand which cellular functions are regulated by ubiquitylation.

Ubiquitin identification and quantification by proteomics analysis
Profacgen offers ubiquitin identification and quantification services for protein in cells or tissues. The work starts from enzymes digestion, peptides enrichment, mass spectrometry analysis and bioinformatics analysis.

Advantages of ubiquitination services offered by Profacgen
Rich and comprehensive services
Professional evaluation and experimental design
Stable platform and accurate data
Timely feedback on project progress

Moreover, to assist scientist better with their drug discovery research, Profacgen has established a comprehensive PROTAC technology platform and services including E3 Ligase and Target Proteins Development, Ligand Discovery and Design, PROTAC In Vitro and In Vivo Evaluations, and Targeted Protein Degradation.

"In addition, we have built a mature computer-aided drug design technology platform, which can greatly accelerate your research process. We offer customized and one-stop PROTAC development services and strive to solve all challenging obstacles during your PROTAC research." Said Crystal, the chief marketing staff at Profacgen.

More detailed information about the custom protein ubiquitination service at Profacgen can be viewed here: https://www.profacgen.com/custom-protein-ubiquitination-services.htm.

Profacgen, Shirley, NY 11967, USA


Email: contact@profacgen.com
Tel: 1-516-855-7709
Address: 45-1 Ramsey Road, Shirley, NY 11967, USA


Profacgen is a state-of-the-art protein service provider located in Long Island, NY, USA. We provide custom protein services in the biological sciences, enabling access to the latest tools, techniques, and expertise with competitive pricing and rapid turnaround time. We serve a broad spectrum of industrial and academic clients with a commitment to delivering high-quality data and customer services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Profacgen Provides Protein Ubiquitination Services to Accelerate Drug Development Project here

News-ID: 2638269 • Views:

More Releases from Profacgen

Profacgen Enhanced Its Structure-based Virtual Screening (SBVS) Service Recently
Profacgen, a biotechnology company that provides custom protein services in the biological sciences, recently enhanced its structure-based virtual screening service for scientists in the field of drug discovery and lead optimization. In structure-based virtual screening (SBVS), potential compounds are computationally docked into the 3D structure of the biological target using biophysical techniques including X-ray crystallography, NMR spectroscopy, and cryo-electron microscopy, homology modeling, or molecular dynamics simulation. Then, the projected binding affinity

More Releases for PROTAC

New Technology of PROTACs
Most of the drugs currently in clinical use are based on small molecules and use the "occupancy-driven" mode of action to inhibit the function of proteins and play a role in the treatment of diseases. Different from traditional small molecule inhibitors and antagonists, protein degradation technology has developed rapidly in recent years because of its ability to induce the degradation of therapeutic target proteins, providing a new idea for the
PROteolysis Targeting Chimera (PROTAC) Market Key-Players and Forecast Research …
The Global PROteolysis Targeting Chimera (PROTAC) Market Report is a valuable source of insightful data for business strategists. It provides the industry overview with growth analysis and historical & futuristic cost, revenue, demand, and supply data (as applicable). The research analysts provide an elaborate description of the value chain and its distributor analysis. This Market study provides comprehensive data that enhances the understanding, scope, and application of this report. "Due to Financial Year
PROteolysis Targeting Chimera (PROTAC) Market to Witness Huge Growth by Key Play …
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the PROteolysis Targeting Chimera (PROTAC) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The PROteolysis Targeting Chimera (PROTAC) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the PROteolysis Targeting Chimera (PROTAC)
Targeted Protein Degradation Market, 2021-2030
Targeted protein degradation has emerged as a revolutionary pharmacological concept that presents both viable and versatile drug development opportunities and is anticipated to introduce a new paradigm in modern healthcare London Roots Analysis has announced the addition of “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings. Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the
The targeted protein degradation enabling technologies market, featuring a healt …
Targeted protein degradation has emerged as a revolutionary pharmacological concept that presents both viable and versatile drug development opportunities and is anticipated to introduce a new paradigm in modern healthcare London Roots Analysis has announced the addition of “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings. Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the
The targeted protein degradation market is projected to grow at an annualized ra …
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to